A concept of soluble receptors in bronchial asthma

Functioning of soluble receptors, mainly soluble cytokine receptors, has been of interest to researchers since the last decade of the 20th century. Allergists’ interest in the issues of soluble receptors is relevant to our studies in the pathogenesis of bronchial asthma (BA), specifically, development of ectopic chemosensory signaling systems, including ectopic bitter taste receptors Tas2R, and signaling pathways of the Receptor for Advanced Glycation End products (RAGE). The expression of soluble receptors in BA was investigated in both studies. The article discusses the mechanisms of soluble receptor formation: 1) proteolytic cleavage of existing membrane receptors; 2) synthesis and release of soluble receptors lacking a transmembrane domain via alternative mRNA splicing; 3) release of membrane receptors in exosomes. Possible functional effects of soluble receptors are considered, i.e., neutralization of corresponding ligands (decoy receptors), ligand transport, ligand stabilization, and binding of membrane proteins. The results of studies of soluble receptors in health and disease are sometimes contradictory and not fully understood. Soluble receptors may be considered prospective therapeutic agents. Our previous data concerning probable functions of a number of soluble Tas2R38, Tas2R31, Tas2R5 receptors are considered when studying the patients with asthma in view of earlier knowledge of the soluble receptors functioning. The most important characteristics of the soluble receptors studied in BA are: 1) lower plasma levels of all discussed Tas2Rs in allergic asthma compared to nonallergic forms; 2) an inverse correlation between plasma Tas2R levels and bronchial resistance; 3) correlation of Tas2Rs with monocyte-macrophages, granulocytes and bronchial ciliated cells. The regulatory role of soluble receptors involved in asthma pathogenesis, mainly cytokines, as well as sTas2R and sRAGE, can be viewed through the corresponding membrane receptor functions. In this case, soluble forms of receptors play the role of decoy proteins that block functions mediated by membrane receptors. In this approach, the discussed soluble cytokine receptors and sRAGE have a positive regulatory effect in BA, whereas sTas2R exert negative action. The balance of soluble and membrane-bound receptor functions in cells involved in asthma pathogenesis is crucial for developing the novel therapies for asthma by targeting the Tas2R and RAGE receptors.

1. Vitkina T.I., Sidletskaya K.A. The role of interleukin-6 signaling in development of systemic inflammation in chronic obstructive pulmonary disease. Byulleten fiziologii i patologii dykhaniya = Bulletin Physiology and Pathology of Respiration, 2018, no. 69, pp. 97-106. (In Russ.)

2. Gusev E.Yu., Zotova N.V., Zhuravleva Yu.A., Chereshnev V.A. Physiological and pathogenic role of scavenger receptors in humans.Meditsinskaya Immunologiya = Medical Immunology (Russia), 2020, Vol. 22, no. 1, pp. 7-48. (In Russ.) doi:10.15789/1563-0625-PAP-1893.

3. Ketlinsky S.A., Simbirtsev A.S. Cytokines. St. Petersburg: Foliant, 2008. 552 p.

4. Mineev V.N. Ectopic olfactory receptors in the respiratory system. Pulmonologiya = Russian Pulmonology, 2019, Vol. 29, no. 6, pp. 734-738. (In Russ.)

5. Mineev V.N. Ectopic photoreceptors in bronchial asthma: possible pathogenetic role. Immunopatologiya, allergologiya, infektologiya = Immunopathology, Allergology, Infectology, 2020, no. 2, pp. 34-40. (In Russ.)

6. Mineev V.N., Nyoma M.A., Trofimov V.I. Ectopic taste buds TAS2R31 in blood serum in different types of bronchial asthma. Tikhookeanskiy meditsinskiy zhurnal = Pacific Medical Journal, 2021, no. 1, pp. 68-71. (In Russ.)

7. Mineev V.N., Sorokina L.N. Protein glycation phenomenon in bronchial asthma. Universitetskiy terapevticheskiy vestnik = University Therapeutic Journal, 2023, Vol. 5, no. 4, pp. 73-81. (In Russ.)

8. Mineev V.N., Sorokina L.N., Trofimov V.I., Nema M.A., Ivanov V.A. Interleukin-4 and -13 receptors: structure, function, and genetic polymorphism. Pulmonologiya= Russian Pulmonology, 2010, no. 3, pp. 113-119. (In Russ.)

9. Mineev V.N., Trofimov V.I., Nyoma M.A., Kuzikova A.A. Bitter taste receptors in serum of patients with asthma (a hypothesis). Pulmonologiya= Russian Pulmonology, 2017, Vol. 27, no. 5, pp. 567-572. (In Russ.)

10. Nyoma M.A., Mineev V.N., Murkina R.G., Sadovaya V.V. Association of plasma levels of the TAS2R5 ectopic taste receptor with clinical and functional characteristics of bronchial asthma. Universitetskiy terapevticheskiy vestnik = University Therapeutic Journal, 2025, Vol. 7, no. 2, pp. 84-92. (In Russ.)

11. Novikov V.V. Soluble Differentiation Molecules in Inflammatory Processes (The Second Life of Proteins): Monograph. Nizhny Novgorod: Gladkova O.V. Izdatelskiy salon, 2022. 212 p.

12. Sigidin Ya.A., Lukina G.V. The drug etanercept in modern rheumatology. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice, 2010, Vol. 48, no. 3, pp. 78-82. (In Russ.)

13. Simbirtsev A.S. Immunopharmacological aspects of the cytokine system. Byulleten sibirskoy meditsiny = Bulletin of Siberian Medicine, 2019, Vol. 18, no. 1, pp. 84-95. (In Russ.)

14. Sorokina L.N., Mineev V.N., Pavlova A.S., Trofimov V.I. The role of the receptor for advanced glycation endproducts (RAGE) in the pathogenesis of asthma. Pulmonologiya = Pulmonologiya, 2025, Vol. 35, no. 1, pp. 95-101. (In Russ.)

15. Aderka D., Engelmann H., Maor Y., Brakebusch C., Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp. Med., 1992, Vol. 175, no. 2, pp. 323-329.

16. Bae E., Cha R.H., Kim Y.C., An J.N., Kim D.K., Yoo K.D., Lee S.M., Kim M.H., Park J.T., Kang S.W., Park J.Y., Lim C.S., Kim Y.S., Yang S.H., Lee J.P. Circulating TNF receptors predict cardiovascular disease in patients with chronic kidney disease. Medicine, 2017, Vol. 96, no. 19, e6666. doi: 10.1097/MD.0000000000006666.

17. Bien E., Balcerska A. Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers, 2008, Vol. 13, no. 1, pp. 1-26.

18. Cameron L., Christodoulopoulos P., Lavigne F., Nakamura Y., Eidelman D., McEuen A., Walls A., Tavernier J., Minshall E., Moqbel R., Hamid Q. Evidence for local eosinophil differentiation within allergic nasal mucosa: inhibition with soluble IL-5 receptor. J. Immunol., 2000, Vol. 164, no. 3, pp. 1538-1545.

19. Crawley A.M., Faucher S., Angel J.B. Soluble IL-7R alpha (sCD127) inhibits IL-7 activity and is increased in HIV infection. J. Immunol., 2010, Vol. 184, no. 9, pp. 4679-4687.

20. Eissner G., Kirchner S., Lindner H., Kolch W., Janosch P., Grell M., Scheurich P., Andreesen R., Holler E. Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages. J. Immunol., 2000, Vol. 164, no. 12, pp. 6193-6198.

21. Ekoff M., Choi J.H., James A., Dahlén B., Nilsson G., Dahlén S.E. Bitter taste receptor (TAS2R) agonists inhibit IgE-dependent mast cell activation. J. Allergy Clin. Immunol., 2014, Vol. 134, no. 2, pp. 475-478.

22. Gohda T., Niewczas M.A., Ficociello L.H., Walker W.H., Skupien J., Rosetti F., Cullere X., Johnson A.C., Crabtree G., Smiles A.M., Mayadas T.N., Warram J.H., Krolewski A.S. Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J. Am. Soc. Nephrol., 2012, Vol. 23, no. 3, pp. 516-524.

23. Hayakawa H., Hayakawa M., Kume A., Tominaga S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J. Biol. Chem., 2007, Vol. 282, no. 36, pp. 26369-26380.

24. Heaney M.L., Golde D.W. Soluble receptors in human disease. J. Leukoc. Biol., 1998, Vol. 64, no. 2, pp. 135-146.

25. Hytönen A.M., Löwhagen O., Arvidsson M., Balder B., Björk A.L., Lindgren S., Hahn-Zoric M., Hanson L.A., Padyukov L. Haplotypes of the interleukin-4 receptor alpha chain gene associate with susceptibility to and severity of atopic asthma. Clin. Exp. Allergy, 2004, Vol. 34, no. 10, pp. 1570-1575.

26. Kefaloyianni E. Soluble forms of cytokine and growth factor receptors: mechanisms of generation and modes of action in the regulation of local and systemic inflammation. FEBS Lett., 2022, Vol. 596, no. 5, pp. 589-606.

27. Levine S.J. Molecular mechanisms of soluble cytokine receptor generation. J. Biol. Chem., 2008, Vol. 283, no. 21, pp. 14177-14181.

28. Lokau J., Garbers C. Biological functions and therapeutic opportunities of soluble cytokine receptors. Cytokine Growth Factor Rev., 2020, Vol. 55, no. 4, pp. 94-108.

29. Lundström W., Highfill S., Walsh S.T., Beq S., Morse E., Kockum I., Alfredsson L., Olsson T., Hillert J., Mackall C.L. Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity. Proc. Natl. Acad. Sci. U. S. A., 2013, Vol. 110, no. 19, pp. E1761-1770.

30. Maier L.M., Anderson D.E., Severson C.A., Baecher-Allan C., Healy B., Liu DV., Wittrup K.D., de Jager P.L., Hafler D.A. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J. Immunol., 2009, Vol. 182, no. 3, pp. 1541-1547.

31. Mantovani A., Locati M., Vecchi A., Sozzani S., Allavena P. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends Immunol., 2001, Vol. 22, no. 6, pp. 328-336.

32. Milutinovic P.S., Alcorn J.F., Englert J.M., Crum L.T., Oury T.D. The receptor for advanced glycation end products is a central mediator of asthma pathogenesis. Am. J. Pathol., 2012, Vol. 181, no. 4, pp. 1215-1225.

33. Mohler K.M., Torrance D.S., Smith C.A., Goodwin R.G., Stremler K.E., Fung V.P., Madani H., Widmer M.B. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol., 1993, Vol. 151, no. 3, pp. 1548-1561.

34. Orsmark-Pietras C., James A., Konradsen J.R., Nordlund B., Söderhäll C., Pulkkinen V., Pedroletti C., Daham K., Kupczyk M., Dahlén B., Kere J., Dahlén S.E., Hedlin G., Melén E. Transcriptome analysis reveals upregulation of bitter taste receptors in severe asthmatics. Eur. Respir. J., 2013, Vol. 42, no. 1, pp. 65-78.

35. Rubin L.A., Kurman C.C., Fritz M.E., Biddison W.E., Boutin B., Yarchoan R., Nelson, D. L. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J. Immunol., 1985, no. 135, pp. 3172-3177.

36. Sato T.A., Widmer M.B., Finkelman F.D., Madani H., Jacobs C.A., Grabstein K.H., Maliszewski C.R. Recombinant soluble murine IL-4 receptor can -inhibit or enhance IgE responses in vivo. J. Immunol., 1993, Vol. 150, no. 7, pp. 2717-2723.

37. Schumertl T., Lokau J., Rose-John S., Garbers C. Function and proteolytic generation of the soluble interleukin-6 receptor in health and disease. Biochim. Biophys. Acta Mol. Cell Res., 2022, Vol. 1869, no. 1, 119143. doi: 10.1016/j.bbamcr.2021.119143.

38. Silvestri T., Pulsatelli L., Dolzani P., Facchini A., Meliconi R. Elevated serum levels of soluble interleukin-4 receptor in osteoarthritis. Osteoarthritis Cartilage, 2006, Vol. 14, no. 7, pp. 717-719.

39. Tong A., Yang H., Yu X., Wang D., Guan J., Zhao M., Li J. Mechanisms and novel therapeutic roles of bitter taste receptors in diseases. Theranostics, 2025, Vol. 15, no. 9, pp. 3961-3978.

40. Vallejo-Vaz A.J. Novel biomarkers in heart failure beyond natriuretic peptides – the case for soluble ST2. Eur. Cardiol., 2015, Vol. 10, no. 1, pp. 37-41.

41. Wilson T.M., Maric I., Shukla J., Brown M., Santos C., Simakova O., Khoury P., Fay M.P., Kozhich A., Kolbeck R., Metcalfe D.D., Klion A.D. IL-5 receptor α levels in patients with marked eosinophilia or mastocytosis. J. Allergy Clin. Immunol., 2011, Vol. 128, no. 5, pp. 1086-1092.e1-3.

42. Zhang H., Deng T., Liu R., Bai M., Zhou L., Wang X., Li S., Wang X., Yang H., Li J., Ning T., Huang D., Li H., Zhang L., Ying G., Ba Y. Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis. Nat. Commun., 2017, Vol. 8, 15016. doi: 10.1038/ncomms15016.